Citigroup Inc Spruce Biosciences, Inc. Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$1.28 - $2.23 $1,015 - $1,768	-793 Reduced 66.86%	393 $1,000
Q1 2022 May 12, 2022	SELL	$1.85 - $4.59 $1,888 - $4,686	-1,021 Reduced 46.26%	1,186 $3,000
Q4 2021 Feb 10, 2022	BUY	$2.33 - $5.74 $1,926 - $4,746	827 Added 59.93%	2,207 $10,000
Q3 2021 Nov 10, 2021	BUY	$6.01 - $11.26 $8,293 - $15,538	1,380 New	1,380 $8,000

15.4M

16.7K

1.1K

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $9.66M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.